Current Practice in the Treatment of Haemophilia

References

• Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. United Kingdom Haemophilia Centre Directors' Organisation Executive Committee. Haemophilia, 3, 63–77, 1997.
   Google Scholar
• UK Regional Haemophilia Centre Directors' Committee. Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A, haemophilia B and von Willebrand's disease. Blood Coagualtion and Fibrinolysis, 3, 205–14, 1992.
   PubMed Web of Science ®Google Scholar
• Hay C. R. M., Colvin, B. T., Ludlam, C. A., Hill, F. G. H. and Preston, F. E. (1996). Recommendations for the treatment of factor VIII inhibitors from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagulation and Fibrinolysis, 7, 134–8.
   PubMed Web of Science ®Google Scholar
• Preston, F. E., Dusheiko, G., Lee, C. A., Ludlam, C. A. and Giangrande, P. L. F. (1995). Guidelines in the diagnosis and management of chronic liver disease in haemophiliacs. Haemophilia, 1(4), 42–4.
   PubMed Web of Science ®Google Scholar
• Guidelines for treating HIV infection-consenus view from UK Haemophilia Centre Directors' Organisation.*
   Google Scholar
• Guidelines for the diagnosis and management of von Willebrand Disease: prepared by the von Willebrand Working party of the United Kingdom Haemophilia Centre Directors' Organisation. Haemophilia, 2, 1–25, 1997.
   Google Scholar
• Guidelines for the use of Factor XI concentrate.*
   Google Scholar
• Prophylaxis in the treatment of haemophilic boys.* * Available from Miss RJD Spooner, Oxford Haemophilia Centre, Churchill Hospital, Headington, Oxford OX3 7LJ, UK.
   Google Scholar
• Tuddenham, E. G. D., Cooper, D. N., Gitschier, J. et al. (1991). Haemophilia A. Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acid Res., 19, 4821–33.
   PubMed Web of Science ®Google Scholar
• Naylor, J. A., Green, P. M., Rizza, C. R. and Giannelli, F. (1992). Factor VIII gene explains all cases of haemophilia A. Lancet, 340, 1066–67.
   PubMed Web of Science ®Google Scholar
• Naylor, J., Brinke, A., Hassock, S., Green, P. M. and Giannelli, F. (1993). Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. Hum. Mol. Genet., 2, 1773–8.
   PubMed Web of Science ®Google Scholar
• Goodeve, A., Preston, F. E. and Peake, I. R. (1994). Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet, 343, 329–30.
   PubMed Web of Science ®Google Scholar
• Lakich, D., Kazazian Jr., H. H., Antonarakis, S. E. and Gitschier, J. (1993). Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nature Genet., 5, 236–41.
   PubMed Web of Science ®Google Scholar
• Giannelli, F., Green, P. M., High, K. A. et al. (1992). Haemophilia B. Database of point mutations and short additions and deletions-third edition. Nucleic Acid Res., 20, 2027–2063.
   PubMed Web of Science ®Google Scholar
• Gitschier, J., Kogan, S., Diamond, C. and Levinson, B. (1991). Genetic basis of haemophilia A. Thromb Haemost., 66, 37–9.
   PubMed Web of Science ®Google Scholar
• Hoyer, L. W. (1994). Haemophilia A. N. Engl. J. Med., 330, 38–47.
   PubMed Web of Science ®Google Scholar
• Darby, S. C., Ewart, D. W., Giangrande, P. L. F., Dolin, P. J., Spooner, R. J. D. and Rizza, C. R. (1995). Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature, 377, 79–82.
   PubMed Web of Science ®Google Scholar
• Kasper, C. K. and Kipnis, S. A. (1972). Hepatitis and clotting-factor concentrates. JAMA, 221, 510.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M. (1992). Outbreak of hepatitis A among Italian patients with haemophilia. Lancet, 339, 819.
   PubMed Web of Science ®Google Scholar
• Santagostino, E., Mannucci, P. M., Gringeri, A., Azzi, A. and Morfini, M. (1994). Eliminating parvovirus B19 from blood products. Lancet, 343, 798.
   PubMed Web of Science ®Google Scholar
• Lee, C. A. (1995). Hepatitis C. and haemophilia. Br. Med. J., 310, 1619–1620.
   PubMedGoogle Scholar
• Telfer, P., Sabin, C., Devereux, H., Scott, F., Dusheiko, G. and Lee, C. (1994). The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br. J. Haematol., 87, 555–61.
   PubMed Web of Science ®Google Scholar
• Telfer, P., Devereux, H., Colvin, B., Hayden, S., Dusheiko, G. and Lee, C. (1995). Alpha interferon for hepatitis C virus infection in haemophilic patients. Haemophilia, 1, 54–8.
   PubMed Web of Science ®Google Scholar
• Sultan, Y. (1992). Prevalence of inhibitors in a population of 3435 haemophilia patients in France: French Haemophilia Study group. Thromb Haemost, 67, 600–2.
   PubMed Web of Science ®Google Scholar
• Ehrenforth, S., Kreuz, W., Scharrer, I. et al. (1992). Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594–8.
   PubMed Web of Science ®Google Scholar
• Lusher, J. M., Arkin, S., Abildgaard, C. F. and Schwartz, R. S. and the Kogenate Previously Untreated Patient Study Group (1993). Recombinant factor VIII for the treatment of previously untreated patients with haemophilia. N. Engl. J. Med., 328, 453–459.
   PubMed Web of Science ®Google Scholar
• Nilsson, I. M., Berntorp, E. and Zettervall, O. (1988). Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N. Engl. J. Med., 318, 947–50.
   PubMed Web of Science ®Google Scholar
• Kasper, C. K. (1989). Treatment of factor VIII inhibitors. Prog Hemost Thromb, 9, 57–86.
   PubMedGoogle Scholar
• Brettler, D. B., Forsberg, A. D., Levine, P. H. et al. (1989). The use of porcine factor VIII concentrate (Hyate C) in the treatment of patients with inhibitor antibodies to factor VIII, a multicentre US experience. Arch. Intern. Med., 149, 1381–5.
   PubMedGoogle Scholar
• Lusher, J. M., Shapiro, S. S., Palascak, J. E. et al. (1980). Efficacy of prothrombin complex concentrates in haemophiliacs with antibodies to factor VIII: a multicentre therapeutic trial. N. Engl. J. Med., 303, 421–5.
   PubMed Web of Science ®Google Scholar
• Sjamsoedin, L. J. M., Heijnen, L., Mauser-Bunschoten, E. P. et al. (1981). The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII: a double blind clinical trial. N. Engl. J. Med., 305, 717–21.
   PubMed Web of Science ®Google Scholar
• Hedner, U., Glazer, S., Pigel, K. et al. (1988). Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy. Lancet, 2, 1193.
   PubMed Web of Science ®Google Scholar
• Slocombe, G. W., Newland, A. C., Colvin, M. P. and Colvin, B. T. (1981). The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. Br. J. Haematol., 47, 577–85.
   PubMed Web of Science ®Google Scholar
• Nilsson, I. M., Jonsson, S., Sundqvist, S.-B., Ahlberg, A. and Bergentz, B.-E. (1981). A procedure for removing high titre antibodies by extracorporeal protein-Asepharose adsorption in haemophilia: substitution therapy and surgery in a patient with haemophilia B and antibodies. Blood, 58, 38–44.
   PubMed Web of Science ®Google Scholar
• Pool, J. G., Hershgold, E. J. and Pappenhagen, A. R. (1964). High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature, 302, 312.
   Web of Science ®Google Scholar
• White, G. C. II, Courter, S., Bray, G. L., Lee, M. and Gomperts, E. D. and the Recombinate Previously Treated Patient Study Group (1997). A multicentre study of recombinant factor VIII (Recombinate™) in previously treated patients with haemophilia A. Thromb Haemost, 77, 660–667.
   PubMed Web of Science ®Google Scholar
• Azzi, A., Ciappi, S., Zakvrewska, K., Morfini, M., Mariani, G. and Mannucci, P. M. (1992). Human parvovirus B19 infection in hemophiliacs first infused with two high purity virally attenuated factor VIII concentrates. Am. J. Hematol., 39, 228–30.
   PubMed Web of Science ®Google Scholar
• Peerlinck, K., Amout, J., Gillies, J. G., Saint-Remy, J. M. and Vermylen, J. (1993). A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost, 69, 115–8.
   PubMed Web of Science ®Google Scholar
• Rosendaal, F. R., Nieuwenhuis, H. K., Van, B. et al. (1993). A sudden increase in factor VIII inhibitor development in multitransfused haemophilia patients in the Netherlands. Blood, 81, 2180–6.
   PubMed Web of Science ®Google Scholar
• Cuthbert, R. J. G., Ludlam, C. A., Steel, C. M., Beatson, D. and Peutherer, J. F. (1992). Immunological studies in HIV seronegative haemophiliacs: relationship to blood product therapy. Br. J. Haematol., 80, 364–369.
   PubMed Web of Science ®Google Scholar
• Seremetis, S. V., Aledort, L. M., Bergman, G. E. et al. (1993). Three year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom free HIV-positive haemophiliacs, effects on immune status. Lancet, 342, 700–3.
   PubMed Web of Science ®Google Scholar
• de Biasi, R., Rocino, A., Miraglia, E., Mastrullo, L. and Quirino, A. A. (1991). The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected haemophiliacs, a randomized prospective, two year comparison with an intermediate purity concentrate. Blood, 78, 1919–22.
   PubMed Web of Science ®Google Scholar
• Cash, J. D., Gader, A. M. A., Da Costa, J. et al. (1975). The release of plasminogen activator and factor VII by LVP, AVP, DDAVP, ATIII and OT in man. Br. J. Haematol., 27, 363–364.
   Google Scholar
• Mannucci, P. M., Aberg, M., Nilsson, I. M. and Robertson, B. (1975). Mechanisms of plasminogen activator and factor VIII increase after vasoactive drugs. Br. J. Haematol., 30, 81–93.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M., Bettega, D. and Cattaneo, M. (1992). Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br. J. Haematol., 82, 87–93.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M., Ruggeri, Z. M., Pareti, F. I. and Capitanio, A. (1977). 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands, disease. Lancet, i, 869–72.
   Google Scholar
• Kobayashi, I. (1979). Treatment of haemophilia A and von Willebrand's disease patients with intranasal dripping of DDAVP. Thromobosis Res., 16, 775–779.
   PubMed Web of Science ®Google Scholar
• Lethagen, S., Harris, A. S., Sjorin, E. and Nilsson, I. M. (1987). Intranasal and intravenous administration of desmopressin: effect on FVIII, vWF, pharmacokinetics and reproducibility. Thromb Haemost, 58, 1033–6.
   PubMed Web of Science ®Google Scholar
• Bonar, J. and Shepherd, B. L. (1996). Treatment of menorrhagia during menstruation, randomised controlled trial of ethamsylate, mefanamic acid and tranexamic acid. Br. Med. J., 313, 579–82.
   PubMedGoogle Scholar
• Henry, D. A. and O'Connell, D. C. (1989). Effect of fibrinolytic inhibitors on mortality from gastro-intestinal haemorrhage. Br. Med. J., 298, 1142–46.
   PubMed Web of Science ®Google Scholar
• MacMillian, C. W., Webster, W. P., Roberts, H. R. and Blythe, W. B. (1970). Continuous intravenous infusion of factor VIII in classic haemophilia. Br. J. Haematol., 18, 659–667.
   PubMed Web of Science ®Google Scholar
• Martinowitz, U., Schulman, S., Gitel, S., Horozowski, H., Heim, M. and Varon, D. (1992). Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br. J. Haematol., 82, 729–34.
   PubMed Web of Science ®Google Scholar
• Hathaway, W. E., Christian, M. J., Clarke, S. L. and Hasiba, U. (1984). Comparison of continuous and intermittent factor VIII concentrate in hemophilia A. Am. J. Haematol., 17, 85–88.
   PubMed Web of Science ®Google Scholar
• Weinstein, R. E., Bona, R. D. and Rickles, F. R. (1991). Continuous infusion of monoclonal antibody-purified factor VIII. Am. J. Haematol., 36, 211–212.
   PubMed Web of Science ®Google Scholar
• Colvin, B.T., Aston, C., Davis, G., Jenkins, G. C. and Dormandy, K. M. (1977). Regional co-ordinator for haemophilia in domiciliary practice. Br. Med. J., 2, 814–815.
   PubMedGoogle Scholar
• Cahill, M. R., Woosey, C. P., Hayden, S. M., MacClean, M. and Colvin, B. T. (1995). Implementation of a nurse practitioner policy for the requisition and administration of drugs in a haemophilia comprehensive care centre. Haemophilia, 1, 172–174.
   PubMed Web of Science ®Google Scholar
• Jones, P. (1992). Haemophilia home therapy. Haemostasis, 22, 247–50.
   PubMedGoogle Scholar
• Nilsson, I. M., Bemtorp, E., Lofqvist, T. and Pettersson, H. (1992). Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J. Int. Med., 232, 25–32.
   PubMed Web of Science ®Google Scholar
• NHS Management Executive Provision of haemophilia treatment and care. Health Service Guidelines, HSG 1993 (30).
   Google Scholar
• Lerut, J. P., Laterre, P. F., Lavenne-Pardonge, E. et al. (1996). Liver transplantation for Haemophilia A. J. Hepatol., 22, 583–585.
   Web of Science ®Google Scholar
• McCarthy, M., Gane, E., Pereira, S. et al. (1996). Liver transplantation for haemophiliacs with hepatitis C cirrhosis. Gut, 39, 870–875.
   PubMed Web of Science ®Google Scholar
• Gene therapy for haemophilia. Pasi, K. J. (1997). Bailliere's Clinical Haematology, 9, 305–317.
   Google Scholar